Alpha Tau's Alpha DaRT Shows Promising Survival Gains in Pancreatic Cancer Trials — Alpha Tau Medical Ltd.

Event summary

Alpha Tau's Alpha DaRT treatment demonstrated median overall survival (mOS) of 11.2 months in metastatic pancreatic cancer patients and 11.1 months in locally advanced patients after first-line chemotherapy, compared to historical data of 4-6 months and ~9 months respectively.
Pooled analysis of three Phase I/II studies showed favorable safety profile with 36% treatment-associated adverse events and 9% Grade ≥3 events, with no treatment-related deaths or chronic toxicity.
Company plans to complete recruitment in the U.S. IMPACT trial, exploring Alpha DaRT in combination with front-line chemotherapy for unresectable pancreatic cancer.
Additional trials include the ACAPELLA study in France and percutaneous delivery approach research at the University of Verona.

The big picture

Alpha Tau's Alpha DaRT represents a novel approach to treating pancreatic cancer, a disease with notoriously poor survival rates. The promising Phase I/II data positions Alpha DaRT as a potential disruptive therapy, particularly for patients who have limited treatment options after failing standard chemotherapy. The company's strategic focus on combination therapies and global clinical trials reflects its ambition to establish Alpha DaRT as a cornerstone in pancreatic cancer treatment regimens.

What we're watching

Clinical Validation: Whether Alpha DaRT can sustain these survival benefits in larger, controlled trials and gain regulatory approval for broader use.
Combination Therapies: The pace at which Alpha Tau can demonstrate Alpha DaRT's efficacy when combined with emerging systemic therapies, potentially expanding its market potential.
Global Expansion: How quickly Alpha Tau can scale its clinical program internationally, particularly in key markets like the U.S. and Europe.